C1galt1-KO 基因敲除小鼠

下单100%中奖,最高可得千元京东卡
复苏/繁育服务
产品名称

C1galt1-KO 基因敲除小鼠

产品编号

S-KO-15545

品系全称

C57BL/6JCya-C1galt1em1/Cya

品系背景

C57BL/6JCya

品系编号

KOCMP-94192-C1galt1-B6J-VA

品系状态

使用本品系发表的文献需注明: C1galt1-KO 基因敲除小鼠 mice (Strain S-KO-15545) were purchased from Cyagen.
交付类型
周龄
性别
基因型
数量

基本信息

基因研究概述

质控标准

基因
基因全称
core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1
基因别称
2210410E06Rik,T-synthase
染色体号
Chr 6 (Mouse)
转录本 ID
NCBI: NM_052993.3 | Ensembl: ENSMUST00000040159
修饰方式
全身性基因敲除
靶向范围
Exon 3
敲除长度
~1.5 kb
品系说明
该品系是基于策略设计时的数据库信息制作而成,建议您在购买前查询最新的数据库和相关文献,以获取最准确的表型信息。
表型提示
MGI:2151071Embryos homozygous for a null allele show impaired angiogenesis, chaotic microvascular networks in brain, and fatal hemorrhage by E14. Eggs homozygous for another null allele show a slightly thinner zona pellucida. Mice homozygous for an ENU-induced allele develop thrombocytopenia and renal disease.
C1galt1基因,也称为核心1合成酶糖蛋白-N-乙酰半乳糖胺3-β-半乳糖基转移酶1,是一种重要的糖基转移酶,负责在O-连接糖基化过程中将半乳糖基转移至核心1结构。C1galt1基因的编码产物C1GALT1在多种生理和病理过程中发挥重要作用,包括细胞粘附、信号转导、细胞增殖和肿瘤发生。

C1GALT1的异常表达与多种癌症的发生和进展相关。例如,胰腺导管腺癌(PDAC)中C1GALT1的表达下调,导致截断的O-糖基结构(如Tn和sTn)水平升高,这些结构可能与肿瘤的侵袭性和转移性相关[1]。在骨肉瘤中,C1GALT1的表达上调,并且其抑制可以减少肿瘤细胞的增殖[2]。在胶质母细胞瘤中,C1GALT1的高表达与较差的生存率相关,并且其下调可以抑制肿瘤细胞的增殖、侵袭和迁移[3]。在膀胱癌中,C1GALT1的表达上调,并且其抑制可以减少肿瘤细胞的迁移和增殖[4]。在卵巢癌中,C1GALT1的表达上调,并且其下调可以减少肿瘤细胞的生长、迁移和球形成[7]。在胆管癌中,C1GALT1的表达下调,并且其抑制可以增加肿瘤细胞的增殖和5-氟尿嘧啶耐药性[8]。在头颈癌中,C1GALT1的表达上调,并且其抑制可以减少肿瘤细胞的增殖、迁移和侵袭[9]。

C1GALT1的异常表达还与IgA肾病的发生相关。例如,C1GALT1的表达下调与血清中缺乏半乳糖的IgA1水平升高相关,这是IgA肾病的一个关键特征[5]。此外,C1GALT1的表达下调还与甲状腺癌的发生相关,并且其抑制可以减少肿瘤细胞的增殖、迁移和侵袭[6]。

综上所述,C1galt1基因编码的C1GALT1在多种生理和病理过程中发挥重要作用,包括细胞粘附、信号转导、细胞增殖和肿瘤发生。C1GALT1的异常表达与多种癌症的发生和进展相关,包括胰腺癌、骨肉瘤、胶质母细胞瘤、膀胱癌、卵巢癌、胆管癌和头颈癌。C1GALT1的异常表达还与IgA肾病和甲状腺癌的发生相关。因此,C1GALT1可能是一个有潜力的治疗靶点,可以用于多种癌症和IgA肾病的治疗。

参考文献:
1. Chugh, Seema, Barkeer, Srikanth, Rachagani, Satyanarayana, Ponnusamy, Moorthy P, Batra, Surinder K. 2018. Disruption of C1galt1 Gene Promotes Development and Metastasis of Pancreatic Adenocarcinomas in Mice. In Gastroenterology, 155, 1608-1624. doi:10.1053/j.gastro.2018.08.007. https://pubmed.ncbi.nlm.nih.gov/30086262/
2. Watanabe, Kentaro, Tasaka, Keiji, Ogata, Hideto, Ogawa, Seishi, Takita, Junko. 2024. Inhibition of the galactosyltransferase C1GALT1 reduces osteosarcoma cell proliferation by interfering with ERK signaling and cell cycle progression. In Cancer gene therapy, 31, 1049-1059. doi:10.1038/s41417-024-00773-9. https://pubmed.ncbi.nlm.nih.gov/38622340/
3. Su, Yanting, Ao, Xin, Long, Yunfeng, Yu, You, Xu, Bo. 2024. C1GALT1 high expression enhances the progression of glioblastoma through the EGFR-AKT/ERK cascade. In Cellular signalling, 125, 111513. doi:10.1016/j.cellsig.2024.111513. https://pubmed.ncbi.nlm.nih.gov/39561885/
4. Tan, Zengqi, Jiang, Yazhuo, Liang, Liang, Li, Xiang, Guan, Feng. 2022. Dysregulation and prometastatic function of glycosyltransferase C1GALT1 modulated by cHP1BP3/ miR-1-3p axis in bladder cancer. In Journal of experimental & clinical cancer research : CR, 41, 228. doi:10.1186/s13046-022-02438-7. https://pubmed.ncbi.nlm.nih.gov/35864552/
5. Wang, Yan-Na, Zhou, Xu-Jie, Chen, Pei, Lv, Ji-Cheng, Zhang, Hong. 2021. Interaction between GALNT12 and C1GALT1 Associates with Galactose-Deficient IgA1 and IgA Nephropathy. In Journal of the American Society of Nephrology : JASN, 32, 545-552. doi:10.1681/ASN.2020060823. https://pubmed.ncbi.nlm.nih.gov/33593824/
6. Huang, Li, Li, Zhen, Xu, Ziguang, Kong, Lingfei, Xia, Zhengchao. 2024. C1GALT1 induces the carcinogenesis of thyroid cancer through regulation by miR-141-3p and GLUT1. In Heliyon, 10, e31778. doi:10.1016/j.heliyon.2024.e31778. https://pubmed.ncbi.nlm.nih.gov/38845937/
7. Chou, Chih-Hsing, Huang, Miao-Juei, Liao, Ying-Yu, Chen, Chi-Hau, Huang, Min-Chuan. . C1GALT1 Seems to Promote In Vitro Disease Progression in Ovarian Cancer. In International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 27, 863-871. doi:10.1097/IGC.0000000000000965. https://pubmed.ncbi.nlm.nih.gov/28498248/
8. Khiaowichit, Juthamas, Talabnin, Chutima, Dechsukhum, Chavaboon, Silsirivanit, Atit, Talabnin, Krajang. 2022. Down-Regulation of C1GALT1 Enhances the Progression of Cholangiocarcinoma through Activation of AKT/ERK Signaling Pathways. In Life (Basel, Switzerland), 12, . doi:10.3390/life12020174. https://pubmed.ncbi.nlm.nih.gov/35207462/
9. Lin, Mei-Chun, Chien, Pin-Hui, Wu, Hsin-Yi, Lou, Pei-Jen, Huang, Min-Chuan. 2018. C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer. In Oncogene, 37, 5780-5793. doi:10.1038/s41388-018-0375-0. https://pubmed.ncbi.nlm.nih.gov/29930379/